SIRPA Antikörper (FITC)
Kurzübersicht für SIRPA Antikörper (FITC) (ABIN2478803)
Target
Alle SIRPA Antikörper anzeigenReaktivität
Wirt
Klonalität
Konjugat
Applikation
Klon
-
-
Produktmerkmale
- Purified IgG conjugated to Fluorescein Isothiocyanate Isomer 1 (FITC)
-
Isotyp
- IgG2a
-
-
anti-Signal-Regulatory Protein alpha (SIRPA) (AA 28-507) antibody
SIRPA Reaktivität: Human WB, ELISA, IF Wirt: Maus Monoclonal 4C7 unconjugated
anti-Signal-Regulatory Protein alpha (SIRPA) (AA 235-373) antibodySIRPA Reaktivität: Human FACS, ELISA Wirt: Maus Monoclonal 2H7E2 unconjugated
anti-Signal-Regulatory Protein alpha (SIRPA) (AA 395-504) antibodySIRPA Reaktivität: Human WB, IF Wirt: Kaninchen Polyclonal unconjugated
anti-Signal-Regulatory Protein alpha (SIRPA) (AA 105-324) antibodySIRPA Reaktivität: Human WB Wirt: Kaninchen Polyclonal unconjugated
anti-Signal-Regulatory Protein alpha (SIRPA) (AA 56-296) antibodySIRPA Reaktivität: Maus WB, IHC, IP, ICC Wirt: Kaninchen Polyclonal unconjugated
anti-Signal-Regulatory Protein alpha (SIRPA) antibodySIRPA Reaktivität: Human WB, IF Wirt: Kaninchen Monoclonal unconjugated
anti-Signal-Regulatory Protein alpha (SIRPA) (C-Term) antibodySIRPA Reaktivität: Human, Maus, Ratte WB, ELISA, IHC, IF, ICC Wirt: Kaninchen Polyclonal unconjugated
anti-Signal-Regulatory Protein alpha (SIRPA) (Internal Region) antibodySIRPA Reaktivität: Human WB, ELISA Wirt: Kaninchen Polyclonal unconjugated
anti-Signal-Regulatory Protein alpha (SIRPA) (AA 31-373) antibodySIRPA Reaktivität: Human ELISA, IHC, IF Wirt: Kaninchen Polyclonal unconjugated
anti-Signal-Regulatory Protein alpha (SIRPA) antibody (FITC)SIRPA Reaktivität: Human FACS Wirt: Maus Monoclonal 15-414 FITC
-
-
Applikationshinweise
- Optimal working dilution should be determined by the investigator.
-
Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
-
-
Format
- Liquid
-
Konzentration
- 0.1 mg/mL
-
-
- SIRPA (Signal-Regulatory Protein alpha (SIRPA))
-
Andere Bezeichnung
- CD172a
-
Hintergrund
- Synonyms: SIRP ALPHA
-
Gen-ID
- 25528
-
UniProt
- P97710
Target
-
